Item 7.01 Regulation FD Disclosure.
On January 27, 2021, KemPharm, Inc., or the Company, issued a press release to
announce that the U.S. Food and Drug Administration, or the FDA, has completed
its review of the Investigational New Drug, or IND, application for KP879, or
KP879 IND, concluding that the Company may proceed with its planned clinical
investigation of the product candidate. The Company expects to initiate the
clinical program for KP879 in 2021. In addition, the Company reported that
it has completed its multi-phase process to regain its Nasdaq listing and to
restructure its balance sheet. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 7.01, and the press release furnished as
Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, and are not incorporated by
reference into any of the Company's filings under the Securities Act of 1933, as
amended, whether made before or after the date hereof, except as shall be
expressly set forth by specific reference in any such filing.
Item 8.01 Other Events.
On January 27, 2021, the Company announced that the FDA completed its review of
the KP879 IND, concluding that the Company may proceed with its planned clinical
investigation of the product candidate. In addition, the Company reported that
it has completed its multi-phase process to regain its Nasdaq listing and to
restructure its balance sheet.
On January 26, 2021, the Company reported that it entered into a warrant
exchange and inducement transaction with certain of holders of the warrants from
the January 8, 2021 offering, the Offering Warrants, whereby such holders agreed
to exercise for cash the Offering Warrants to purchase 6,620,358 shares of the
Company's common stock in exchange for the Company's agreement to issue new
warrants to purchase up to 7,944,430 shares of the Company's common stock, which
is equal to 120% of the number of shares of the Company's common stock issued
upon exercise of the Offering Warrants. As a result of this transaction, the
Company will receive gross proceeds of approximately $44.0 million. The Company
intends to use approximately $8.0 million of the proceeds from the warrant
exchange and inducement transaction to repay the remaining debt, including the
related prepayment premium.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release titled "KemPharm Receives FDA Clearance to Initiate
KP879 Clinical Program for the Treatment of Stimulant Use
Disorder" dated January 27, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses